These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 32869672)
1. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold? Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672 [TBL] [Abstract][Full Text] [Related]
2. How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy. Heuser M; Mina A; Stein EM; Altman JK Am Soc Clin Oncol Educ Book; 2019 Jan; 39():411-420. PubMed ID: 31099617 [TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia. Kirtonia A; Pandya G; Sethi G; Pandey AK; Das BC; Garg M J Mol Med (Berl); 2020 Aug; 98(8):1069-1091. PubMed ID: 32620999 [TBL] [Abstract][Full Text] [Related]
6. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434 [TBL] [Abstract][Full Text] [Related]
7. Novel treatments for relapsed/refractory acute myeloid leukemia with Tallis E; Borthakur G Expert Rev Hematol; 2019 Aug; 12(8):621-640. PubMed ID: 31232619 [No Abstract] [Full Text] [Related]
8. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches. Grieselhuber NR; Mims AS Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705 [TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia. Yang F; Anekpuritanang T; Press RD Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884 [TBL] [Abstract][Full Text] [Related]
10. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy. Sami SA; Darwish NHE; Barile ANM; Mousa SA Curr Treat Options Oncol; 2020 Jan; 21(1):3. PubMed ID: 31933183 [TBL] [Abstract][Full Text] [Related]
11. Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia. Ma J; Ge Z Bosn J Basic Med Sci; 2021 Aug; 21(4):409-421. PubMed ID: 33577442 [TBL] [Abstract][Full Text] [Related]
12. Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet? Chung C; Ma H Pharmacotherapy; 2017 Sep; 37(9):1052-1072. PubMed ID: 28654205 [TBL] [Abstract][Full Text] [Related]
13. Precision medicine in acute myeloid leukemia: Hope, hype or both? Prasad V; Gale RP Leuk Res; 2016 Sep; 48():73-7. PubMed ID: 27497757 [TBL] [Abstract][Full Text] [Related]
14. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199. Naqvi K; Konopleva M; Ravandi F Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432 [TBL] [Abstract][Full Text] [Related]
16. Updates on targeted therapies for acute myeloid leukaemia. Kayser S; Levis MJ Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585 [TBL] [Abstract][Full Text] [Related]
17. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia? Bewersdorf JP; Stahl M; Zeidan AM Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518 [TBL] [Abstract][Full Text] [Related]